Biotage AB in brief
Biotage AB is a listed company in the Medical Instruments industry, based in Sweden. Its last known market value was $1.0 B (January 2024); there is no current figure. In the year to December 2024 it had sales of $195 M and a net profit of $27 M, about 14 cents of profit for every dollar of sales. Its shares trade under the symbol BIOT.ST (Stockholm).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Biotage AB
Biotage offer workflow solutions and products to customers in drug discovery and development, analytical testing and water and environmental testing. They serve their customers in the market segments of pharmaceutical, biotech, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability. The company annual revenue is 1,232 million SEK and annual net income is 205 million SEK as on 2021. The headquarters is in Sweden.
Biotage AB timeline
- 1997
- 🏁· approximateIncorporated as Biotage AB
- 2016
- •Legal Entity Identifier issuedLEI 529900SR87NBUKX74L58 registered.
Events of Biotage AB from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Sweden: #116 (Jan 2020) · #127 (Jan 2021) · #125 (Jan 2022) · #101 (Dec 2022) · #116 (Jul 2023) · #121 (Jan 2024)
Key ratios
- P/E ratio
- —
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- 13.8%
- Operating margin
- 18.6%
- Return on equity
- 7.2%
- Liabilities / assets
- 19.4%
- Revenue growth
- +11.0%
- R&D / revenue
- 8.8%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $195M | +11.0% | $36M | $27M | 13.8% |
| Dec 2023 | $175M | — | $30M | $23M | 13.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $39M | $8M | $31M | $0.34 | — |
| Dec 2023 | $27M | $2M | $24M | $0.31 | — |
Annual results
- Revenue
- $195 M
- Operating income
- $36 M
- Net income
- $27 M
For year ending December-2024 · source: official annual report (ESEF)
Balance sheet
- Total assets
- $463 M
- Total liabilities
- $90 M
- Total equity
- $373 M
As of December-2024
Ownership and subsidiaries
- Biotage Sweden AB🇸🇪 Uppsala
Biotage AB scorecard#
Passes 4 of the 5 checks that could be worked out. Fiscal year 2024.
Valuationnot known
Growth2 of 2
Profitability2 of 3
Financial healthnot known
Shareholder returnsnot known
Worked out from the statements as filed (esef), the medians of Medical Instruments, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2024#
Worked out from Biotage AB's statements, beside the median of Medical Instruments.
| Ratio | Trend | 2024 | Median of peers |
|---|---|---|---|
| Operating margin | 18.6% | 7.0% | |
| Net margin | 13.8% | 3.3% | |
| Return on equity | 7.3% | 2.4% | |
| Revenue growth | 11.0% | 8.3% | |
| Free cash flow margin | 15.8% | 5.5% |
6of 6on the Piotroski tests of financial strength
Biotage AB: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in SEK millions; per-share figures in SEK; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 2,056 | 1,862 | 1,566 | 1,232 | 1,092 | |
| Cost of revenue | 767 | 713 | 618 | 477 | 426 | |
| Gross profit | 1,289 | 1,149 | 948 | 755 | 667 | |
| Research and development | 180 | 159 | 109 | 91 | 72 | |
| General and administrative | 264 | 212 | 150 | 117 | 105 | |
| Operating income | 383 | 314 | 327 | 271 | 206 | |
| Interest and finance income | 12 | 30 | 35 | 10 | 26 | |
| Interest expense and finance costs | 67 | 41 | 14 | 12 | 9.0 | |
| Income before tax | 328 | 303 | 348 | 269 | 223 | |
| Income tax | 44 | 57 | 80 | 64 | 47 | |
| Net income including minority interests | 284 | 246 | 268 | 205 | 175 | |
| Net income attributable to shareholders | 284 | 246 | 268 | 205 | 175 | |
| Earnings per share, basic | 3.55 | 3.34 | 4.06 | 3.13 | 2.69 | |
| Earnings per share, diluted | 3.55 | 3.33 | 4.04 | 3.13 | 2.69 | |
| Shares, weighted average (basic) | 80 | 74 | 66 | 65 | 65 | |
| Shares, weighted average (diluted) | 80 | 74 | 66 | 65 | 65 | |
| Dividends per share | 1.65 | — | 1.60 | — | — | |
| Balance sheet | ||||||
| Cash and cash equivalents | 434 | 594 | 441 | 311 | 371 | |
| Receivables | 357 | 321 | 223 | 180 | 194 | |
| Inventory | 458 | 437 | 305 | 237 | 160 | |
| Current assets | 1,323 | 1,447 | 1,031 | 774 | 752 | |
| Property, plant and equipment | 245 | 187 | 96 | 76 | 53 | |
| Right-of-use (leased) assets | 85 | 97 | 66 | 52 | 51 | |
| Goodwill | 2,563 | 2,391 | 794 | 741 | 290 | |
| Other intangible assets | — | — | 172 | 185 | 129 | |
| Non-current assets | 3,746 | 3,484 | 1,308 | 1,218 | 683 | |
| Total assets | 5,104 | 4,931 | 2,339 | 1,992 | 1,434 | |
| Accounts payable | — | — | 57 | 56 | 51 | |
| Current liabilities | 573 | 705 | 417 | 313 | 217 | |
| Long-term debt | 150 | 150 | 150 | 150 | 110 | |
| Lease liabilities (non-current) | 66 | 76 | 42 | 30 | 31 | |
| Non-current liabilities | 409 | 569 | 285 | 307 | 227 | |
| Total liabilities | — | — | — | — | 1,434 | |
| Retained earnings | 1,537 | 1,378 | 1,229 | 1,063 | 956 | |
| Total equity | 4,113 | 3,657 | 1,637 | 1,371 | 990 | |
| Total liabilities and equity | 5,104 | 4,931 | 2,339 | 1,992 | — | |
| Shares outstanding | — | — | 66 | 66 | 65 | |
| Cash-flow statement | ||||||
| Cash from operating activities | 413 | 284 | 341 | 353 | 279 | |
| Capital expenditure | −89 | −26 | −35 | −23 | −18 | |
| Intangible assets bought | −80 | −65 | −35 | −33 | −43 | |
| Acquisitions, net of cash acquired | −287 | −125 | −12 | −282 | 0 | |
| Cash from investing activities | −456 | 35 | −84 | −341 | −62 | |
| Debt issued | — | — | 150 | 150 | 0 | |
| Debt repaid | −30 | −38 | −180 | −134 | — | |
| Shares issued | 2.0 | 0 | — | — | — | |
| Shares bought back | — | — | 0 | 0 | 0 | |
| Dividends paid | −128 | −106 | −102 | −98 | 0 | |
| Cash from financing activities | −156 | −142 | −133 | −82 | −23 | |
| Exchange-rate effect on cash | 39 | −24 | 7.0 | 9.0 | −10 | |
| Report | ESEF | ESEF | ESEF | ESEF | ESEF | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Dec 31, 2024
Where Biotage AB operates: 1 country#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
Only the headquarters country is on file for Biotage AB: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.
| Country | Presence | Revenue there |
|---|---|---|
| 🇸🇪 Sweden | Headquarters2 offices1 subsidiary | — |
How Biotage AB compares in Medical Instruments
- Revenue$195 M · higher than 32% of 121
- Net margin13.8% · higher than 69% of 115
- Revenue growth11.0% · higher than 59% of 50
Peer comparison · Medical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Biotage AB🇸🇪 | $1.0 B | — | 13.8% | +11.0% |
| Intuitive Surgical, Inc.🇺🇸 | $155.6 B | 52.6× | 25.5% | +20.5% |
| EssilorLuxottica S.A.🇫🇷 | $88.0 B | 32.1× | 8.1% | +4.5% |
| HOYA Corporation🇯🇵 | $56.2 B | 32.8× | 25.4% | — |
| Becton, Dickinson and Company🇺🇸 | $54.0 B | 57.4× | 4.2% | +8.2% |
| Alcon Inc.🇨🇭 | $37.1 B | 37.9× | 9.4% | +4.9% |
| ResMed Inc.🇺🇸 | $35.3 B | 22.1× | 27.8% | +9.8% |
| West Pharmaceutical Services, Inc.🇺🇸 | $27.1 B | 42.4× | 18.8% | +6.3% |
| Terumo Corporation🇯🇵 | $24.9 B | 27.0× | 12.0% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Intuitive Surgical, Inc.$155.6 B
- EssilorLuxottica S.A.$88.0 B
- HOYA Corporation$56.2 B
- Becton, Dickinson and Company$54.0 B
- Alcon Inc.$37.1 B
- ResMed Inc.$35.3 B
How current the figures are
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Profile updated:
- Nov 15, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Biotage AB? Verify and update this profile — free
Show Biotage AB's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.